IFRX - インフラRx (InflaRx N.V.) インフラRx

 IFRXのチャート


 IFRXの企業情報

symbol IFRx
会社名 InflaRx NV (インフラRx)
分野(sector)   
産業(industry)   
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Inflarx NV formerly Fireman BV is a holding company for InflaRx GmbH a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate IFX-1 is an intravenously delivered first-in-class anti-C5a monoclonal antibody undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS) a rare and chronic debilitating systemic inflammatory skin disease and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2 which is in preclinical development.   インフラRxはドイツのバイオ医薬品企業。米国において、C5a技術を使用し阻害剤の発見・開発に従事する。同社のC5a技術は自己免疫疾患や炎症性疾患の治療のために開発され、腹水炎の予防のために静脈内に送達された抗C5aモノクロ―ナル抗体IFX-1の開発に関与している。また、ANCA関連血管炎の治療にIFX-2が開発される。   InflaRx is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA.
本社所在地 Winzerlaer Strasse 2 Jena 07745 DEU
代表者氏名
代表者役職名
電話番号 +49 3641-50-8180
設立年月日 42887
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 21人
url www.inflarx.com
nasdaq_url https://www.nasdaq.com/symbol/ifrx
adr_tso
EBITDA EBITDA(百万ドル) -33.47187
終値(lastsale) 34.3
時価総額(marketcap) 880210030
時価総額 時価総額(百万ドル) 839.85550
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 660.17260
当期純利益 当期純利益(百万ドル) -32.84556
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Inflarx NV revenues was not reported. Net loss increased 51% to EUR12.8M. Higher net loss reflects Research and development expenses increase of 91% to EUR10.5M (expense) General and administrative expenses increase from EUR1.3M to EUR6.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -EUR0.36 to -EUR0.51.

 IFRXのテクニカル分析


 IFRXのニュース

   InflaRx initiates mid-stage vilobelimab skin cancer trial  2021/06/08 11:52:28 Seeking Alpha
   InflaRx N.V. Shares Fall 4.2% Below Previous 52-Week Low - Market Mover  2021/05/13 22:30:00 Kwhen Finance
InflaRx N.V. (IFRX) shares closed 4.2% lower than its previous 52 week low, giving the company a market cap of $123M. The stock is currently down 43.3% year-to-date, down 64.4% over the past 12 months, and down 81.0% over the past five years. This week, the Dow Jones Industrial Average fell 1.8%, and the S&P 500 fell 2.5%. Trading Activity Trading volume this week was 459.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -346.0% The company's stock price performance over the past 12 months lags the peer average by -249.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   InflaRx N.V. Shares Fall 12.0% Below Previous 52-Week Low - Market Mover  2021/05/12 22:30:00 Kwhen Finance
InflaRx N.V. (IFRX) shares closed 12.0% lower than its previous 52 week low, giving the company a market cap of $150M. The stock is currently down 31.0% year-to-date, down 56.4% over the past 12 months, and down 76.9% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 267.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -229.9% The company's stock price performance over the past 12 months lags the peer average by -209.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   InflaRx N.V. Shares Close the Day 17.9% Lower - Daily Wrap  2021/05/12 22:30:00 Kwhen Finance
InflaRx N.V. (IFRX) shares closed today 17.9% lower than it did at the end of yesterday. The stock is currently down 31.0% year-to-date, down 56.4% over the past 12 months, and down 76.9% over the past five years. Today, the Dow Jones Industrial Average fell 2.0%, and the S&P 500 fell 2.1%. Trading Activity Shares traded as high as $3.70 and as low as $3.24 this week.Shares closed 7e+1% below its 52-week high and 1e+1% below its 52-week low.Trading volume this week was 203.8% higher than the 10-day average and 273.0% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -229.9% The company's stock price performance over the past 12 months lags the peer average by -209.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   InflaRx reports Q1 results  2021/05/12 11:41:13 Seeking Alpha
   The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs  2019/11/07 10:38:02 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 6) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally following positive Adcom verdict for Twirla) Constellation Pharmaceuticals Inc (NASDAQ: CNST )(announced positive results from a Phase 2 trial of CPI-0610 in combination with Jakafi in myelofibrosis) Exagen Inc (NASDAQ: XGN ) INNATE PHARMA S/S ADR (NASDAQ: IPHA ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Viela Bio Inc (NASDAQ: VIE ) (IPOed Oct. 3) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 6) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO ) Biocept Inc (NASDAQ: BIOC ) bluebird bio Inc (NASDAQ: BLUE ) Cocrystal Pharma Inc (NASDAQ: COCP ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Exelixis, Inc.
   The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering  2019/08/06 11:22:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc.
   InflaRx Enters Oversold Territory  2019/06/13 14:18:00 Zacks Investment Research
InflaRx N.V. (IFRX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
   The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering  2019/06/06 11:37:34 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 5) Array Biopharma Inc (NASDAQ: ARRY ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) EXACT Sciences Corporation (NASDAQ: EXAS ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Misonix, Inc. (NASDAQ: MSON ) Repligen Corporation (NASDAQ: RGEN ) Uniqure NV (NASDAQ: QURE ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on June 5) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CELLECT BIOTECH/S ADR (NASDAQ: APOP ) ChemoCentryx Inc (NASDAQ: CCXI )(moved in sympathy with its rival, which has a competing drug) Collegium Pharmaceutical Inc (NASDAQ: COLL ) ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Harvard Bioscience, Inc.
   InflaRx N.V. (IFRX) Reports Q1 Loss, Lags Revenue Estimates  2019/05/23 13:15:03 Zacks Investment Research
InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 30.65% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
   The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs  2019/11/07 10:38:02 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 6) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally following positive Adcom verdict for Twirla) Constellation Pharmaceuticals Inc (NASDAQ: CNST )(announced positive results from a Phase 2 trial of CPI-0610 in combination with Jakafi in myelofibrosis) Exagen Inc (NASDAQ: XGN ) INNATE PHARMA S/S ADR (NASDAQ: IPHA ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Viela Bio Inc (NASDAQ: VIE ) (IPOed Oct. 3) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 6) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO ) Biocept Inc (NASDAQ: BIOC ) bluebird bio Inc (NASDAQ: BLUE ) Cocrystal Pharma Inc (NASDAQ: COCP ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Exelixis, Inc.
   The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering  2019/08/06 11:22:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc.
   InflaRx Enters Oversold Territory  2019/06/13 14:18:00 Zacks Investment Research
InflaRx N.V. (IFRX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
   The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering  2019/06/06 11:37:34 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 5) Array Biopharma Inc (NASDAQ: ARRY ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) EXACT Sciences Corporation (NASDAQ: EXAS ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Misonix, Inc. (NASDAQ: MSON ) Repligen Corporation (NASDAQ: RGEN ) Uniqure NV (NASDAQ: QURE ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on June 5) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CELLECT BIOTECH/S ADR (NASDAQ: APOP ) ChemoCentryx Inc (NASDAQ: CCXI )(moved in sympathy with its rival, which has a competing drug) Collegium Pharmaceutical Inc (NASDAQ: COLL ) ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Harvard Bioscience, Inc.
   InflaRx N.V. (IFRX) Reports Q1 Loss, Lags Revenue Estimates  2019/05/23 13:15:03 Zacks Investment Research
InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 30.65% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 インフラRx IFRX InflaRx N.V.)

 twitter  (公式ツイッターやCEOツイッターなど)